384 related articles for article (PubMed ID: 25904556)
1. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
3. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
4. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
9. Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
Choong KC; Su X; Urban MO
Neurosci Lett; 2007 Mar; 414(2):105-9. PubMed ID: 17194542
[TBL] [Abstract][Full Text] [Related]
10. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
[TBL] [Abstract][Full Text] [Related]
11. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors.
Sacerdote P; Massi P; Panerai AE; Parolaro D
J Neuroimmunol; 2000 Sep; 109(2):155-63. PubMed ID: 10996217
[TBL] [Abstract][Full Text] [Related]
13. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
14. CB2 cannabinoid receptor mediation of antinociception.
Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
[TBL] [Abstract][Full Text] [Related]
15. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
Gkoumassi E; Dekkers BG; Dröge MJ; Elzinga CR; Schmidt M; Meurs H; Zaagsma J; Nelemans SA
Br J Pharmacol; 2007 Aug; 151(7):1041-8. PubMed ID: 17558435
[TBL] [Abstract][Full Text] [Related]
16. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
17. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
[TBL] [Abstract][Full Text] [Related]
18. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
Pryce G; Baker D
Br J Pharmacol; 2007 Feb; 150(4):519-25. PubMed ID: 17220914
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.
Rahn EJ; Zvonok AM; Thakur GA; Khanolkar AD; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2008 Nov; 327(2):584-91. PubMed ID: 18664590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
